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tent Expansion as a
echanical Parameter to
redict Late Stent Patency
ack to the Basics*
asuhiro Honda, MD, Peter J. Fitzgerald, MD, PHD
tanford, California
ver the past decades, a number of studies have searched
he determinants of adverse events following stent implan-
ation. Among several clinical, angiographic, and intravas-
ular ultrasound (IVUS) variables identified in those re-
orts, minimum stent area (MSA) as measured by IVUS is
consistent and powerful predictor for both angiographic
nd clinical restenosis (1). In fact, multiple clinical trials in
he bare-metal stent (BMS) era have shown that IVUS-
uided stent placement improves clinical outcomes as com-
ared with angiographic guidance alone, primarily by
chieving larger acute lumen gain while avoiding increased
See page 1269
omplications (1). However, controversial results were also
eported in a few other BMS studies (2,3), presumably due
o differing criteria for IVUS-guided optimal stenting as
ell as various adjunctive treatment strategies that were
sed in these trials in response to suboptimal results.
urrently, there is a growing clinical demand for clarifying
hether this paradigm learned from BMS remains impor-
ant in the contemporary percutaneous coronary interven-
ions, and, if so, whether an optimal procedural end point
xists to achieve the best clinical outcomes following drug-
luting stent (DES) implantation.
ationale for the Bigger-Is-Better Paradigm
n-stent restenosis is primarily due to excessive biological
esponse within a stented artery—namely neointimal pro-
iferation (4,5). This leads to the question, “Why is MSA, as
mechanical stent parameter, a strong determinant of
estenosis?” It is easy to understand that stent underexpan-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.r
From the Division of Cardiovascular Medicine, Stanford University, Stanford,
alifornia.ion can result in flow-limiting lumen compromise even
ith minimal neointimal hyperplasia. However, this expla-
ation does not fully clarify why achieving even larger stent
rea can further reduce the restenosis rate in BMS—the
o-called bigger-is-better paradigm. To elucidate this
echanism, it is essential to understand the principle of this
ptimization strategy based upon the statistical profile of
n-stent biologic response.
In statistical analysis of a given population, neointimal
olume within BMS generally follows a near-Gaussian,
ell-shaped frequency distribution around a mean value of
0% to 35% (Fig. 1). On its histogram, the mean value
epresents the overall biologic response to the stent, whereas
he width of the distribution curve indicates the degree of
esion-to-lesion variation in arterial response to acute and/or
hronic vessel injury (6). Restenosis, measured as a binary
ariable, corresponds to the area under the right end of the
istribution curve beyond a threshold of neointimal prolifera-
ion. Mathematically, stents with larger MSA can afford a
reater amount of neointima until reaching a flow-limiting
tenosis. Therefore, any type of adjunctive mechanical strategy
o achieve larger acute lumen gain reduces restenosis simply by
aising this threshold (shifting the threshold toward the right)
ather than changing the shape or location of the distribution
urve itself. As a result, even in a range of adequate stent
xpansion, obtaining larger MSA continues to reduce resteno-
is until the threshold passes beyond the right tail end of the
requency curve of neointima.
s Bigger-Is-Better Also Applicable to DES?
pparently from the statistical model discussed above, the
pplicability of the conventional bigger-is-better strategy to
specific new stent device depends on the shape of the right
ail end of the frequency distribution of neointima. For
xample, the bigger-is-better strategy (shifting the thresh-
ld toward the right) would continue to help reduce the
estenosis rate (the area of the right tail end above the
hreshold) of stents with a relatively long tail-end distribu-
ion (i.e., large individual variation of neointimal prolifera-
ion). On the contrary, if a particular stent shows a skewed
r deformed frequency distribution curve of neointima with
short right tail end (i.e., small individual variation), the
enefit of achieving a larger acute gain beyond a certain
oint would be steeply diminished. It is important to note
hat, unlike BMS, significant biologic modification proper-
ies of current DES often result in a non-Gaussian fre-
uency distribution (6). In such DES, the shape and width
f the tail end may not be accurately predicted from the
ean or median value of overall neointimal volume. There-
ore, the applicability and relative benefit of the bigger-is-
etter optimization strategy needs to be judged individually
n each DES, based upon its whole profile of biological
esponse, rather than the representative antiproliferative
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1277ffect expressed as the mean value of neointima (or late loss
y angiography) reported in the literature.
iagnostic Accuracy of MSA for Follow-Up
atency in DES Versus BMS
n this issue of JACC: Cardiovascular Interventions, Doi et al.
7) has extended our insights from an earlier series of IVUS
tudies with BMS and/or sirolimus-eluting stents (8–11) to
atients treated with paclitaxel-eluting stents (PES). Using
ne of the largest-ever reported datasets of PES with IVUS
nterrogation, the study investigated the predictive value of
ost-intervention MSA on 9-month patency of PES versus
MS. As consistently observed in other stent studies,
ultivariate logistic regression analysis identified post-
ntervention MSA as the independent predictor of subse-
uent in-stent restenosis in both PES and BMS. With
eceiver-operator characteristic analysis, the optimal thresh-
ld of MSA that best predicted 9-month stent patency was
eported as 5.7 mm2 for PES and 6.4 mm2 for BMS.
As discussed earlier using the statistical model, the
iagnostic accuracy of MSA for follow-up lumen patency is
function of neointimal variability, rather than the average
ower of neointimal suppression. As an extreme theoretical
xample, if the lesion-to-lesion variation of neointimal
roliferation is 0 (i.e., every patient develops the same
Mean
Threshold
Restenosis
Neointimal Volume
Lesion-to-Lesion Variation in Biologic Response
%
 o
f L
es
io
ns
Figure 1. Frequency Distribution of Neointimal Proliferation Following
Stent Implantation
Neointimal volume within bare-metal stents follows a near-Gaussian distri-
bution, where the width of the distribution curve indicates individual varia-
tion in vascular response. Restenosis corresponds to the right tail end of
the curve above a threshold of tolerable neointima. The bigger-is-better
strategy (shifting the threshold toward the right) would continue to help
reduce the restenosis rate until the threshold line passes beyond the right
tail end.mount of neointima), post-procedural MSA of this partic- blar stent would predict follow-up lumen dimensions with
00% accuracy, regardless of the mean value of neointima.
onversely, even if a mean (or median) amount of neointima
s small, MSA can poorly predict follow-up lumen patency in
tents with relatively large lesion-to-lesion variations.
According to the results reported in the study by Doi et
l. (7), the current PES—TAXUS Express and TAXUS
iberté (Boston Scientific, Natick, Massachusetts)—appear
o have similar diagnostic performance of MSA, as com-
ared with BMS with identical stent platforms. Whereas
he overall antiproliferative effect of PES resulted in a
maller optimal threshold of MSA, the C statistic and odds
atio in predicting 9-month restenosis were virtually iden-
ical for PES and BMS, possibly indicating comparable
egrees of neointimal variation across the lesions treated
ith PES versus BMS. Of note, the lower positive and
igher negative predictive values of PES may have largely
erived from the lower incidence of restenosis in the PES
opulation, rather than possibly suppressed neointimal vari-
bility of PES versus BMS.
ptimal Diagnostic Threshold Versus
rocedural End Point
everal investigator groups, including the authors of this
ditorial, have used receiver-operator characteristic analysis
o evaluate the predictive value of MSA in various stenting
evices (7–11). Unfortunately, however, the optimal diag-
ostic thresholds determined in those studies have often
een misinterpreted by readers as optimal “procedural” end
oints (or criteria for optimal stent deployment). As also
ointed out by Doi et al. (7), those terms are not equal,
imply because to best predict the outcome is not the same as
o predict the best outcome. Technically, a procedural end
oint cannot be determined using a cross-point of sensitivity
nd specificity curves, because the importance of those 2
iagnostic variables are not equivalent from a clinical per-
pective (detecting true restenosis is clinically more impor-
ant than avoiding false-positive diagnosis). An ideal pro-
edural end point should be a clinically reasonable
greement of MSA in maximizing the probability of long-
erm stent patency while minimizing increased risk of
omplications, if any.
ummary
here is compelling evidence that stent underexpansion is a
ignificant contributor to the development of adverse events,
egardless of the stent type (1,6,12–14). In a range of
dequate stent expansion, however, the relative benefit of
urther obtaining larger MSA may significantly vary among
ES, depending on its predictability (or lesion variability)
f subsequent neointimal proliferation. Although the study
y Doi et al. (7) was not intended to identify the criteria for
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1278ptimal stent deployment, the current PES appear to
enefit from a strategy of achieving larger MSA to ensure a
reater “safety margin” for unexpectedly large neointimal
roliferation occasionally developed during follow-up.
iven the wide variety of clinical backgrounds, patient risk
actors, lesion morphologies, and disease complexities that
e routinely face in our clinical practice, it is unlikely that a
ingle pre-specified MSA end point could be effectively
pplied to all target lesions. Nevertheless, the ability of
VUS to assess the result of stent implantation more
recisely than angiography can significantly contribute to
ur clinical judgment for individual patients. A continuing
cientific endeavor, as represented by the study by Doi et al.
7), needs to be mounted for better understanding of the
iological heterogeneity, ultimately leading to definitive
herapies via risk stratification of each target segment.
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